Obesity in type 1 diabetes: an overlooked immune-metabolic issue

References

• Norris JM, Johnson RK, Stene LC. Type 1 diabetes—early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020;8(3):226–238. doi: 10.1016/S2213-8587(19)30412-7
   PubMed Web of Science ®Google Scholar
• Malik VS, Willet WC, Hu FB. Nearly a decade on — trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol. 2020;16(11):615–616. doi: 10.1038/s41574-020-00411-y
   PubMed Web of Science ®Google Scholar
• der Schueren B V, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. The Lancet Diabetes & Endocrinology. 2021;9(11):776–785. doi: 10.1016/S2213-8587(21)00246-1
   PubMed Web of Science ®Google Scholar
• Faradji-Hazán RN, Valenzuela-Lara M, Díaz-Barriga Menchaca AP, et al. Type 1 diabetes care in Mexico: an analysis of the RENACED-DT1 national registry. Rev Invest Clin. 2021;73:222–230. doi: 10.24875/RIC.20000498
   PubMedGoogle Scholar
• Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technology & Therapeutics. 2019;21(2):66–72. doi: 10.1089/dia.2018.0384
   PubMed Web of Science ®Google Scholar
• Fellinger P, Fuchs D, Wolf P, et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr. 2019;131(3–4):55–60. doi: 10.1007/s00508-018-1434-9
   PubMed Web of Science ®Google Scholar
• Lavens A, Nobels F, De Block C, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther. 2021;23(8):565–576. doi: 10.1089/dia.2021.0003
   PubMed Web of Science ®Google Scholar
• DuBose SN, Hermann JM, Tamborlane WV, et al. Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J Pediatr. 2015;167(3):627–632.e4. doi: 10.1016/j.jpeds.2015.05.046
   PubMed Web of Science ®Google Scholar
• Baskaran C, Volkening LK, Diaz M, et al. A decade of temporal trends in overweight/obesity in youth with type 1 diabetes after the diabetes control and complications trial. Pediatr Diabetes. 2015;16(4):263–270. doi: 10.1111/pedi.12166
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2. Arch Intern Med. 2009;169:1307–1316.
   PubMed Web of Science ®Google Scholar
• Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2010;11(1):4–11. doi: 10.1111/j.1399-5448.2009.00519.x
   PubMed Web of Science ®Google Scholar
• Minges KE, Whittemore R, Weinzimer SA, et al. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D exchange clinic registry. Diabet Res Clin Pract. 2017;126:68–78. doi: 10.1016/j.diabres.2017.01.012
   PubMed Web of Science ®Google Scholar
• Vilarrasa N, San Jose P, Rubio MÁ, et al. Obesity in patients with type 1 diabetes: links, risks and management challenges. Diabetes, Metab Syndr Obes Targets Ther. 2021;14:2807–2827. doi: 10.2147/DMSO.S223618
   PubMed Web of Science ®Google Scholar
• Kueh MTW, Chew NWS, Al-Ozairi E, et al. The emergence of obesity in type 1 diabetes. Int J Obes. 2024;48(3):289–301. doi: 10.1038/s41366-023-01429-8
   Web of Science ®Google Scholar
• Jacob AN, Salinas K, Adams-Huet B, et al. Potential causes of weight gain in type 1 diabetes mellitus. Diab Obes Metab. 2006;8(4):404–411. doi: 10.1111/j.1463-1326.2005.00515.x
   PubMed Web of Science ®Google Scholar
• Charlton MR, Nair KS. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998;47(11):1748–1756. doi: 10.2337/diabetes.47.11.1748
   PubMed Web of Science ®Google Scholar
• Greco AV, Tataranni PA, Mingrone G, et al. Daily energy metabolism in patients with type 1 diabetes mellitus. J Am Coll Nutr. 1995;14(3):286–291. doi: 10.1080/07315724.1995.10718509
   PubMed Web of Science ®Google Scholar
• Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284–296. doi: 10.1016/S2213-8587(22)00003-1
   PubMed Web of Science ®Google Scholar
• Stefan N, Schick F, Birkenfeld AL, et al. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236–252. doi: 10.1016/j.cmet.2023.01.006
   PubMed Web of Science ®Google Scholar
• Kupriyanova Y, Zaharia OP, Bobrov P, et al. Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. J Hepatol. 2021;74(5):1028–1037. doi: 10.1016/j.jhep.2020.11.030
   PubMed Web of Science ®Google Scholar
• Oh YS, Bae GD, Baek DJ, et al. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol. 2018;9:384. doi: 10.3389/fendo.2018.00384
   PubMed Web of Science ®Google Scholar
• Kollari E, Zografou I, Sampanis C, et al. Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. Hormones (Athens). 2022;21(1):91–101. doi: 10.1007/s42000-021-00328-9
   PubMedGoogle Scholar
• Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11(5):289–297. doi: 10.1038/nrendo.2015.8
   PubMed Web of Science ®Google Scholar
• Lauria A, Barker A, Schloot N, et al. BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol. 2015;172(2):107–113. doi: 10.1530/EJE-14-0522
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Maddaloni E, Gaglia J, et al. Adult-onset autoimmune diabetes. Nat Rev Dis Prim. 2022;8(1):63. doi: 10.1038/s41572-022-00390-6
   PubMedGoogle Scholar
• Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19(9):542–554. doi: 10.1038/s41574-023-00853-0
   PubMed Web of Science ®Google Scholar
• Kibirige M, Metcalf B, Renuka R, et al. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care. 2003;26(10):2865–2870. doi: 10.2337/diacare.26.10.2865
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13(11):674–686. doi: 10.1038/nrendo.2017.99
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab. 2007;18(2):52–57. doi: 10.1016/j.tem.2006.12.003
   PubMed Web of Science ®Google Scholar
• Keenan HA, Maddaloni E. Bone microarchitecture in type 1 diabetes: it is complicated. Curr Osteoporos Rep. 2016;14(6):351–358. doi: 10.1007/s11914-016-0338-8
   PubMed Web of Science ®Google Scholar